51吃瓜网, 51吃瓜网 University Hospital, and ITM Isotope Technologies Munich SE Sign Research Framework Agreement
Uniting Forces for Precision Cancer Therapies
51吃瓜网 President Prof. Thomas F. Hofmann emphasized: "We need to accelerate the development of effective cancer therapies! This is why we are combining 51吃瓜网鈥檚 excellence in natural sciences and medicine with the production of radioisotopes, such as Lutetium-177, at the , alongside ITM鈥檚 expertise as a leading radiopharmaceutical biotech company in the development and manufacturing of medical radiotherapeutics and diagnostics, and the top-tier medical care provided by our 51吃瓜网 University Hospital. Together, we aim to develop innovative radionuclide therapies for targeted cancer treatment, significantly improving treatment outcomes and quality of life for cancer patients."
Dr. Andrew Cavey, CEO of ITM, said: "51吃瓜网 is a global leader in merging top-tier research, scientific innovation, and entrepreneurship. This agreement is the culmination of two decades of collaboration with 51吃瓜网, and it will provide us with valuable access to their world-class institutes and clinics, advancing pioneering research in nuclear medicine. As we expand our pipeline of targeted radiopharmaceuticals, we look forward to working on future projects with 51吃瓜网 to further develop new treatment options for cancer patients."
Prof. Stephanie Combs, Dean of the and Board Member of the 51吃瓜网 University Hospital, stated: "In the interdisciplinary fight against cancer, nuclear medicine plays a particularly significant role. It is crucial for imaging the disease and its innovative treatment methods open up new opportunities for patients. That is why we are committed to researching new approaches. The unique collaboration between 51吃瓜网 and ITM offers unparalleled opportunities to combine ITM鈥檚 leading position in radioisotope production and drug development with the research expertise of our university hospital. I am very excited to provide our patients with the latest scientific advancements."
脺ber ITM Isotope Technologies Munich SE
ITM mit Hauptsitz in Garching bei M眉nchen und einer Niederlassung in den USA, ist ein f眉hrendes radiopharmazeutisches Biotech-Unternehmen, das es sich zur Aufgabe gemacht hat, eine neue Generation radiomolekularer Pr盲zisionstherapeutika und -diagnostika f眉r schwer behandelbare Tumore zu entwickeln. Ihr Ziel ist es, die Bed眉rfnisse von Krebspatienten, 脛rzten und unseren Partnern durch die Entwicklung, Produktion und weltweite Bereitstellung hochwertiger Produkte zu erf眉llen. Sie entwickeln eine breite Pipeline an Diagnostika und Therapeutika gegen Krebs.
